Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children
Condition: Hepatitis B Interventions: Biological: Recombinant Hepatitis B (Bio Farma) Vaccine; Biological: Recombinant Hepatitis B (Bio Farma) Vaccine® Sponsor: PT Bio Farma Not yet recruiting
Abstract From December 2006 to December 2016, 1093 human immunodeficiency virus (HIV) individuals
ConclusionsReceiving the birth dose is positively associated with up-to-date status later in childhood, highlighting the importance of starting vaccination early. The association is insensitive to confounding by factors observed in National Immunization Survey-Child, but investigation of unobserved factors such as vaccine hesitancy could provide critical information to guide intervention strategy.
The burden of hepatocellular carcinoma (HCC) is highest in East Asia and Africa, although its incidence and mortality are rapidly rising in the United States and Europe. With the implementation of hepatitis B vaccination and hepatitis C treatment programmes worldwide, the epidemiology of HCC is shifting away from a disease predominated by viral hepatitis – an increasing proportion of cases are now attributable to non-alcoholic steatohepatitis. Surveillance using ultrasound, with or without alpha-fetoprotein, every 6 months has been associated with improved early detection and improved overall survival; however, lim...
This study sought to provide up-to-date hepatitis B (HBV) and C (HCV) seroprevalence in rural Burkina Faso decade after hepatitis B vaccine was introduced in the national immunization scheduled for children.
Abstract This was a descriptive study of 30 children born to HBsAG positive mothers between June 2009 and December 2013. All children had anti-HBs response ≤100 IU/L after 3 doses of hepatitis B vaccine primary series. A single booster dose led to hepatitis B surface antibody titers ≥100 IU/L in (85%) of children. PMID: 31937704 [PubMed - in process]
CONCLUSIONS: Both vaccines were effective in inducing anti-HBs levels of ≥10 mIU/ml, and therefore either can be used as a single formula booster at 18 months of age to simplify vaccine administration under the Expanded Program on Immunization in Thailand. PMID: 31948817 [PubMed - as supplied by publisher]
The objectives of the conservative treatment for chronic kidney disease are to slow down the progression of kidney dysfunction, treat complications (anemia, bone diseases, cardiovascular diseases), vaccination for hepatitis B, and preparation for kidney replacement therapy.
PMID: 31948821 [PubMed - as supplied by publisher]